> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – June 2015

Loading EJC News Focus video

RECIST under pressure

RECIST (Response evaluation criteria in solid tumours) has achieved a rare consensus in cancer. It's almost universally used by researchers in different countries and healthcare systems and in almost all types of the disease. But as diagnostics and treatments develop, is it feasible for these criteria to meet all research needs, from early phase I work right through to phase III clinical trials?

Lesley Seymour (NCIC Clinical Trials Group, Canada and co-chair of the RECIST Working Group) and Jan Bogaerts (EORTC, Belgium) respectively chaired and spoke at a 'Beyond RECIST' session at TAT Congress (Paris, France; 2-4 March 2015). Here, they discuss with Helen Saul, the challenges and possibilities for RECIST in future.